person · Reporting owner

Zurbay Donald

Disclosed activity across 7 companies

Tapewire entity: 37172
SEC CIK: 0001341608

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
DENTSPLY SIRONA Inc.XRAY · Entity 4448	Director	June 03, 2026	June 05, 2026
LivaNova PLCLIVN · Entity 507	Director	June 15, 2026	June 17, 2026
Sight Sciences, Inc.SGHT · Entity 5537	Director	June 04, 2026	June 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

DENTSPLY SIRONA Inc.

Report date June 03, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	29,693	Reported balance After 2026-06-03 transaction · row 1 1 source row Row 1 · 2026-06-03 · Grant · Acquired 22,822 · Balance 29,693 F1: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant.

LivaNova PLC

Report date June 15, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	2,252	Ending reported balance After 2026-06-15 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-15 · Exercise / conversion · Acquired 2,560 · Balance 2,560 F1: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), 1.00 GBP par value. F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement. Row 2 · 2026-06-15 · Tax withholding · Disposed 308 · Balance 2,252 F3: Shares withheld to satisfy tax liability.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-15 · Exercise / conversion · Disposed 2,560 · Balance 0 F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement. F4: RSUs granted under the 2025 Plan on September 15, 2025 that vested on June 15, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,383	Reported balance After 2026-06-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-15 · Grant · Acquired 2,383 · Balance 2,383 F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement. F5: The RSUs, granted under the 2025 Plan, vest on June 15, 2027, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), 1.00 GBP par value.

F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement.

F3: Shares withheld to satisfy tax liability.

F4: RSUs granted under the 2025 Plan on September 15, 2025 that vested on June 15, 2026.

F5: The RSUs, granted under the 2025 Plan, vest on June 15, 2027, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.

Sight Sciences, Inc.

Report date June 04, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	193,613	Reported balance After 2026-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 28,261 · Balance 193,613 F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2: Includes (i) 75,352 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 90,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 4, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.

F2: Includes (i) 75,352 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 90,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 4, 2026.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVEDRO INC

Report date November 21, 2019 · Filed November 25, 2019

Section 16 reporting ended · disclosed 2019-11-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-11-21 transaction · row 1 1 source row Row 1 · 2019-11-21 · Disposition to issuer · Disposed 3,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2029-01-08	Direct	Reported balance After 2019-11-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-21 · Disposition to issuer · Disposed 8,314 · Balance 0 F2: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2027-06-26	Direct	Reported balance After 2019-11-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-21 · Disposition to issuer · Disposed 41,941 · Balance 0 F2: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2028-07-17	Direct	Reported balance After 2019-11-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-21 · Disposition to issuer · Disposed 10,224 · Balance 0 F2: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-11-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-21 · Disposition to issuer · Disposed 3,005 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.

F2: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options.

F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.

PATTERSON COMPANIES, INC.

Report date April 17, 2025 · Filed April 17, 2025

Section 16 reporting ended · disclosed 2025-04-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2025-04-17 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2025-04-17 · Grant · Acquired 20,840 · Balance 243,576 F1: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement). F2: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2022 and held by the Reporting Person immediately prior to the closing of the Merger. Row 2 · 2025-04-17 · Grant · Acquired 60,132 · Balance 303,708 F1: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement). F3: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2023 and held by the Reporting Person immediately prior to the closing of the Merger. Row 3 · 2025-04-17 · Grant · Acquired 94,477 · Balance 398,185 F1: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement). F4: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2024 and held by the Reporting Person immediately prior to the closing of the Merger. Row 4 · 2025-04-17 · Disposition to issuer · Disposed 398,185 · Balance 0 F5: Includes an aggregate 131,233 restricted stock units awarded to the Reporting Person pursuant to the Plan in the years 2022 through 2024 and held by the Reporting Person immediately prior to the closing of the Merger. F6: Reflects the disposition of shares of common stock, par value $0.01 per share ("Shares"), of Patterson in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 10, 2024 (the "Merger Agreement"), by and among Patterson, Paradigm Parent, LLC, a Delaware limited liability company ("Parent"), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On April 17, 2025, upon the closing of the merger of Merger Sub with and into Patterson (the "Merger") contemplated by the Merger Agreement, each outstanding Share was cancelled and automatically converted into the right to receive $31.35 in cash, without interest, and minus any applicable withholding taxes. For purposes of Rule 16b-3 of the Exchange Act, Patterson's Board of Directors approved the disposition of all equity securities by the Reporting Person in connection with the merger.
Common StockSEC Table I · non-derivative	IndirectBy KSOP	Reported balance After 2025-04-17 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2025-04-17 · Disposition to issuer · Disposed 1,243 · Balance 0 F6: Reflects the disposition of shares of common stock, par value $0.01 per share ("Shares"), of Patterson in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 10, 2024 (the "Merger Agreement"), by and among Patterson, Paradigm Parent, LLC, a Delaware limited liability company ("Parent"), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On April 17, 2025, upon the closing of the merger of Merger Sub with and into Patterson (the "Merger") contemplated by the Merger Agreement, each outstanding Share was cancelled and automatically converted into the right to receive $31.35 in cash, without interest, and minus any applicable withholding taxes. For purposes of Rule 16b-3 of the Exchange Act, Patterson's Board of Directors approved the disposition of all equity securities by the Reporting Person in connection with the merger. F7: Represents Shares indirectly held by the Reporting Person's Employee Stock Ownership Plan component of their 401(k) (the "KSOP") account immediately prior to the closing of the Merger.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.26 · Expires 2033-07-01	Direct	Reported balance After 2025-04-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-04-17 · Disposition to issuer · Disposed 93,633 · Balance 0 F8: Stock options granted pursuant to the Plan on 7/1/2023. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F9: This option, which vested 33.3% on 7/1/2024, and was originally scheduled to vest 33.3% on 7/1/2025 and 33.4% on 7/1/2026, was cancelled for no consideration, because the exercise price was greater than the Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.99 · Expires 2032-12-05	Direct	Reported balance After 2025-04-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-04-17 · Disposition to issuer · Disposed 134,033 · Balance 0 F11: Stock options granted pursuant to the Plan on 12/5/2022. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F12: This option, which vested 33.3% on 12/5/2023, 33.3% on 12/5/2024 and was originally scheduled to vest 33.4% on 12/5/2025, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.59 · Expires 2032-07-01	Direct	Reported balance After 2025-04-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-04-17 · Disposition to issuer · Disposed 35,895 · Balance 0 F13: Stock options granted pursuant to the Plan on 7/1/2022. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F14: This option, which vested 33.3% on 7/1/2023, 33.3% on 7/1/2024 and was originally scheduled to vest 33.4% on 7/1/2025, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.77 · Expires 2031-07-01	Direct	Reported balance After 2025-04-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-04-17 · Disposition to issuer · Disposed 37,831 · Balance 0 F15: Stock options granted pursuant to the Plan on 7/1/2021. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F16: This option, which vested 33.3% on 7/1/2022, 33.3% on 7/1/2023 and 33.4% on 7/1/2024, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $23.57 · Expires 2030-07-14	Direct	Reported balance After 2025-04-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-04-17 · Disposition to issuer · Disposed 57,819 · Balance 0 F17: Stock options granted pursuant to the Plan on 7/14/2020. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F18: This option, which vested 33.3% on 7/14/2021, 33.3% on 7/14/2022 and 33.4% on 7/14/2023, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.25 · Expires 2029-07-01	Direct	Reported balance After 2025-04-17 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-04-17 · Disposition to issuer · Disposed 78,829 · Balance 0 F19: Stock options granted pursuant to the Plan on 7/1/2019. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F20: This option, which vested 33.3% on 7/1/2020, 33.3% on 7/1/2021 and 33.4% on 7/1/2022, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.48 · Expires 2028-07-01	Direct	Reported balance After 2025-04-17 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-04-17 · Disposition to issuer · Disposed 33,363 · Balance 0 F21: Stock options granted pursuant to the Plan on 7/1/2018. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F22: This option, which vested 100% on 7/1/2021, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.67 · Expires 2028-06-29	Direct	Reported balance After 2025-04-17 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-04-17 · Disposition to issuer · Disposed 99,250 · Balance 0 F23: Stock options granted as an inducement award granted outside the Plan on 6/29/2018. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F24: This option, which vested pro-rata over the course of 3 years, with one-third of the shares vesting on 6/29/2019, one-third vesting on 6/29/2020, and the remaining one-third vesting on 6/29/2021, in all cases subject to continued employment, was cancelled and exchanged for Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement).

F2: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2022 and held by the Reporting Person immediately prior to the closing of the Merger.

F3: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2023 and held by the Reporting Person immediately prior to the closing of the Merger.

F4: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2024 and held by the Reporting Person immediately prior to the closing of the Merger.

F5: Includes an aggregate 131,233 restricted stock units awarded to the Reporting Person pursuant to the Plan in the years 2022 through 2024 and held by the Reporting Person immediately prior to the closing of the Merger.

F6: Reflects the disposition of shares of common stock, par value $0.01 per share ("Shares"), of Patterson in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 10, 2024 (the "Merger Agreement"), by and among Patterson, Paradigm Parent, LLC, a Delaware limited liability company ("Parent"), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On April 17, 2025, upon the closing of the merger of Merger Sub with and into Patterson (the "Merger") contemplated by the Merger Agreement, each outstanding Share was cancelled and automatically converted into the right to receive $31.35 in cash, without interest, and minus any applicable withholding taxes. For purposes of Rule 16b-3 of the Exchange Act, Patterson's Board of Directors approved the disposition of all equity securities by the Reporting Person in connection with the merger.

F7: Represents Shares indirectly held by the Reporting Person's Employee Stock Ownership Plan component of their 401(k) (the "KSOP") account immediately prior to the closing of the Merger.

F8: Stock options granted pursuant to the Plan on 7/1/2023.

F9: This option, which vested 33.3% on 7/1/2024, and was originally scheduled to vest 33.3% on 7/1/2025 and 33.4% on 7/1/2026, was cancelled for no consideration, because the exercise price was greater than the Merger Consideration.

F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration.

F11: Stock options granted pursuant to the Plan on 12/5/2022.

F12: This option, which vested 33.3% on 12/5/2023, 33.3% on 12/5/2024 and was originally scheduled to vest 33.4% on 12/5/2025, was cancelled and exchanged for Merger Consideration.

F13: Stock options granted pursuant to the Plan on 7/1/2022.

F14: This option, which vested 33.3% on 7/1/2023, 33.3% on 7/1/2024 and was originally scheduled to vest 33.4% on 7/1/2025, was cancelled and exchanged for Merger Consideration.

F15: Stock options granted pursuant to the Plan on 7/1/2021.

F16: This option, which vested 33.3% on 7/1/2022, 33.3% on 7/1/2023 and 33.4% on 7/1/2024, was cancelled and exchanged for Merger Consideration.

F17: Stock options granted pursuant to the Plan on 7/14/2020.

F18: This option, which vested 33.3% on 7/14/2021, 33.3% on 7/14/2022 and 33.4% on 7/14/2023, was cancelled and exchanged for Merger Consideration.

F19: Stock options granted pursuant to the Plan on 7/1/2019.

F20: This option, which vested 33.3% on 7/1/2020, 33.3% on 7/1/2021 and 33.4% on 7/1/2022, was cancelled and exchanged for Merger Consideration.

F21: Stock options granted pursuant to the Plan on 7/1/2018.

F22: This option, which vested 100% on 7/1/2021, was cancelled and exchanged for Merger Consideration.

F23: Stock options granted as an inducement award granted outside the Plan on 6/29/2018.

F24: This option, which vested pro-rata over the course of 3 years, with one-third of the shares vesting on 6/29/2019, one-third vesting on 6/29/2020, and the remaining one-third vesting on 6/29/2021, in all cases subject to continued employment, was cancelled and exchanged for Merger Consideration.

ST JUDE MEDICAL, LLC

Report date January 04, 2017 · Filed January 06, 2017

Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-01-04 transaction · row 1 1 source row Row 1 · 2017-01-04 · Disposition to issuer · Disposed 26,075 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.65 · Expires 2018-12-14	Direct	Reported balance After 2017-01-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-01-04 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.96 · Expires 2019-12-12	Direct	Reported balance After 2017-01-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-01-04 · Disposition to issuer · Disposed 42,664 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10	Direct	Reported balance After 2017-01-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-01-04 · Disposition to issuer · Disposed 74,664 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10	Direct	Reported balance After 2017-01-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-01-04 · Disposition to issuer · Disposed 78,212 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2022-12-08	Direct	Reported balance After 2017-01-04 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-01-04 · Disposition to issuer · Disposed 76,440 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.62 · Expires 2023-12-07	Direct	Reported balance After 2017-01-04 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-01-04 · Disposition to issuer · Disposed 101,864 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-01-04 · Disposition to issuer · Disposed 2,346 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-01-04 · Disposition to issuer · Disposed 4,342 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-01-04 · Disposition to issuer · Disposed 8,112 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.

F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.

F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.

F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

Silk Road Medical Inc

Report date September 17, 2024 · Filed September 19, 2024

Section 16 reporting ended · disclosed 2024-09-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-09-17 transaction · row 1 1 source row Row 1 · 2024-09-17 · Disposition to issuer · Disposed 12,610 · Balance 0 F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2028-03-22	Direct	Reported balance After 2024-09-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-09-17 · Disposition to issuer · Disposed 146,031 · Balance 0 F4: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $3,123,603.09, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2028-03-22	Direct	Reported balance After 2024-09-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-09-17 · Disposition to issuer · Disposed 29,206 · Balance 0 F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $448,312.10, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2029-04-03	Direct	Reported balance After 2024-09-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-09-17 · Disposition to issuer · Disposed 8,910 · Balance 0 F6: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Filing footnotes · ownership attribution and instrument terms

F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.

F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.

F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.

F4: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $3,123,603.09, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $448,312.10, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

F6: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 15, 2026 Filed Jun 17, 2026 20:08 UTC	LivaNova PLC LIVN · Entity 507	GrantRestricted Stock Units · Derivative	2,383	$0.00	$0.00	Disclosure SEC source: 0001639691-26-000067 · wk-form4_1781726920.xml · derivative · entry 4 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,383 Underlying: Ordinary Shares · 2,383 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement. F5 · derivative.exercise_date: The RSUs, granted under the 2025 Plan, vest on June 15, 2027, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement. F5 · derivative.expiration_date: The RSUs, granted under the 2025 Plan, vest on June 15, 2027, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement. Read SEC document
June 15, 2026 Filed Jun 17, 2026 20:08 UTC	LivaNova PLC LIVN · Entity 507	Exercise / conversionRestricted Stock Units · Derivative	2,560	$0.00	$0.00	Disclosure SEC source: 0001639691-26-000067 · wk-form4_1781726920.xml · derivative · entry 3 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement. F4 · derivative.exercise_date: RSUs granted under the 2025 Plan on September 15, 2025 that vested on June 15, 2026. F4 · derivative.expiration_date: RSUs granted under the 2025 Plan on September 15, 2025 that vested on June 15, 2026. Read SEC document
June 15, 2026 Filed Jun 17, 2026 20:08 UTC	LivaNova PLC LIVN · Entity 507	Tax withholdingOrdinary Shares	308	$79.70	$24,547.60	Disclosure SEC source: 0001639691-26-000067 · wk-form4_1781726920.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,252 F3 · shares: Shares withheld to satisfy tax liability. Read SEC document
June 15, 2026 Filed Jun 17, 2026 20:08 UTC	LivaNova PLC LIVN · Entity 507	Exercise / conversionOrdinary Shares	2,560	$0.00	$0.00	Disclosure SEC source: 0001639691-26-000067 · wk-form4_1781726920.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), 1.00 GBP par value. F2 · price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement. Read SEC document
June 04, 2026 Filed Jun 5, 2026 20:09 UTC	Sight Sciences, Inc. SGHT · Entity 5537	GrantCommon Stock	28,261	$0.00	$0.00	Disclosure SEC source: 0001193125-26-259558 · ownership.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,613 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) 75,352 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 90,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 4, 2026. Read SEC document
June 03, 2026 Filed Jun 5, 2026 21:38 UTC	DENTSPLY SIRONA Inc. XRAY · Entity 4448	GrantCommon Stock	22,822	$0.00	$0.00	Disclosure SEC source: 0000818479-26-000192 · form4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,693 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document
January 26, 2026 Filed Jan 27, 2026 22:02 UTC	DENTSPLY SIRONA Inc. XRAY · Entity 4448	GrantCommon Stock	6,871	$0.00	$0.00	Disclosure SEC source: 0000818479-26-000047 · form4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,871 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document
September 15, 2025 Filed Sep 17, 2025 20:08 UTC	LivaNova PLC LIVN · Entity 507	GrantRestricted Stock Units · Derivative	2,560	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001639691-25-000137 · wk-form4_1758139698.xml · derivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,560 Underlying: Ordinary Shares · 2,560 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2025 Director Incentive Award Plan (the "Plan") and the award agreement. F2 · derivative.exercise_date: On September 15, 2025, reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 15, 2026, subject to continued service during the vesting period and the award agreement. F2 · derivative.expiration_date: On September 15, 2025, reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 15, 2026, subject to continued service during the vesting period and the award agreement. Read SEC document
June 05, 2025 Filed Jun 10, 2025 01:53 UTC	Sight Sciences, Inc. SGHT · Entity 5537	GrantCommon Stock	30,952	$0.00	$0.00	Disclosure SEC source: 0000950170-25-084068 · ownership.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,352 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 5, 2025. The RSUs vest on the earlier of June 5, 2026 and the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) 44,400 shares of Common Stock, (ii) 30,952 RSUs which are subject to vesting as reported herein, and (iii) 90,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 5, 2025. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Disposition to issuerStock Option · Derivative	99,250	Not disclosed Strike: $22.67	Not disclosed	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · derivative · entry 13 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,250 shares Expires 2028-06-29 F23 · security: Stock options granted as an inducement award granted outside the Plan on 6/29/2018. F10 · price: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F24 · derivative.exercise_date: This option, which vested pro-rata over the course of 3 years, with one-third of the shares vesting on 6/29/2019, one-third vesting on 6/29/2020, and the remaining one-third vesting on 6/29/2021, in all cases subject to continued employment, was cancelled and exchanged for Merger Consideration. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Disposition to issuerStock Option · Derivative	33,363	Not disclosed Strike: $22.48	Not disclosed	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · derivative · entry 12 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,363 shares Expires 2028-07-01 F21 · security: Stock options granted pursuant to the Plan on 7/1/2018. F10 · price: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F22 · derivative.exercise_date: This option, which vested 100% on 7/1/2021, was cancelled and exchanged for Merger Consideration. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Disposition to issuerStock Option · Derivative	78,829	Not disclosed Strike: $22.25	Not disclosed	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · derivative · entry 11 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,829 shares Expires 2029-07-01 F19 · security: Stock options granted pursuant to the Plan on 7/1/2019. F10 · price: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F20 · derivative.exercise_date: This option, which vested 33.3% on 7/1/2020, 33.3% on 7/1/2021 and 33.4% on 7/1/2022, was cancelled and exchanged for Merger Consideration. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Disposition to issuerStock Option · Derivative	57,819	Not disclosed Strike: $23.57	Not disclosed	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · derivative · entry 10 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,819 shares Expires 2030-07-14 F17 · security: Stock options granted pursuant to the Plan on 7/14/2020. F10 · price: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F18 · derivative.exercise_date: This option, which vested 33.3% on 7/14/2021, 33.3% on 7/14/2022 and 33.4% on 7/14/2023, was cancelled and exchanged for Merger Consideration. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Disposition to issuerStock Option · Derivative	37,831	Not disclosed Strike: $30.77	Not disclosed	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · derivative · entry 9 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,831 shares Expires 2031-07-01 F15 · security: Stock options granted pursuant to the Plan on 7/1/2021. F10 · price: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F16 · derivative.exercise_date: This option, which vested 33.3% on 7/1/2022, 33.3% on 7/1/2023 and 33.4% on 7/1/2024, was cancelled and exchanged for Merger Consideration. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Disposition to issuerStock Option · Derivative	35,895	Not disclosed Strike: $30.59	Not disclosed	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · derivative · entry 8 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,895 shares Expires 2032-07-01 F13 · security: Stock options granted pursuant to the Plan on 7/1/2022. F10 · price: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F14 · derivative.exercise_date: This option, which vested 33.3% on 7/1/2023, 33.3% on 7/1/2024 and was originally scheduled to vest 33.4% on 7/1/2025, was cancelled and exchanged for Merger Consideration. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Disposition to issuerStock Option · Derivative	134,033	Not disclosed Strike: $28.99	Not disclosed	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · derivative · entry 7 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 134,033 shares Expires 2032-12-05 F11 · security: Stock options granted pursuant to the Plan on 12/5/2022. F10 · price: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F12 · derivative.exercise_date: This option, which vested 33.3% on 12/5/2023, 33.3% on 12/5/2024 and was originally scheduled to vest 33.4% on 12/5/2025, was cancelled and exchanged for Merger Consideration. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Disposition to issuerStock Option · Derivative	93,633	Not disclosed Strike: $33.26	Not disclosed	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · derivative · entry 6 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,633 shares Expires 2033-07-01 F8 · security: Stock options granted pursuant to the Plan on 7/1/2023. F10 · price: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F9 · derivative.exercise_date: This option, which vested 33.3% on 7/1/2024, and was originally scheduled to vest 33.3% on 7/1/2025 and 33.4% on 7/1/2026, was cancelled for no consideration, because the exercise price was greater than the Merger Consideration. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Disposition to issuerCommon Stock	1,243	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · nonDerivative · entry 5 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By KSOP Disclosed balance after: 0 F6 · shares: Reflects the disposition of shares of common stock, par value $0.01 per share ("Shares"), of Patterson in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 10, 2024 (the "Merger Agreement"), by and among Patterson, Paradigm Parent, LLC, a Delaware limited liability company ("Parent"), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On April 17, 2025, upon the closing of the merger of Merger Sub with and into Patterson (the "Merger") contemplated by the Merger Agreement, each outstanding Share was cancelled and automatically converted into the right to receive $31.35 in cash, without interest, and minus any applicable withholding taxes. For purposes of Rule 16b-3 of the Exchange Act, Patterson's Board of Directors approved the disposition of all equity securities by the Reporting Person in connection with the merger. F7 · shares: Represents Shares indirectly held by the Reporting Person's Employee Stock Ownership Plan component of their 401(k) (the "KSOP") account immediately prior to the closing of the Merger. F6 · price: Reflects the disposition of shares of common stock, par value $0.01 per share ("Shares"), of Patterson in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 10, 2024 (the "Merger Agreement"), by and among Patterson, Paradigm Parent, LLC, a Delaware limited liability company ("Parent"), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On April 17, 2025, upon the closing of the merger of Merger Sub with and into Patterson (the "Merger") contemplated by the Merger Agreement, each outstanding Share was cancelled and automatically converted into the right to receive $31.35 in cash, without interest, and minus any applicable withholding taxes. For purposes of Rule 16b-3 of the Exchange Act, Patterson's Board of Directors approved the disposition of all equity securities by the Reporting Person in connection with the merger. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Disposition to issuerCommon Stock	398,185	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · nonDerivative · entry 4 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · shares: Includes an aggregate 131,233 restricted stock units awarded to the Reporting Person pursuant to the Plan in the years 2022 through 2024 and held by the Reporting Person immediately prior to the closing of the Merger. F6 · shares: Reflects the disposition of shares of common stock, par value $0.01 per share ("Shares"), of Patterson in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 10, 2024 (the "Merger Agreement"), by and among Patterson, Paradigm Parent, LLC, a Delaware limited liability company ("Parent"), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On April 17, 2025, upon the closing of the merger of Merger Sub with and into Patterson (the "Merger") contemplated by the Merger Agreement, each outstanding Share was cancelled and automatically converted into the right to receive $31.35 in cash, without interest, and minus any applicable withholding taxes. For purposes of Rule 16b-3 of the Exchange Act, Patterson's Board of Directors approved the disposition of all equity securities by the Reporting Person in connection with the merger. F6 · price: Reflects the disposition of shares of common stock, par value $0.01 per share ("Shares"), of Patterson in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 10, 2024 (the "Merger Agreement"), by and among Patterson, Paradigm Parent, LLC, a Delaware limited liability company ("Parent"), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On April 17, 2025, upon the closing of the merger of Merger Sub with and into Patterson (the "Merger") contemplated by the Merger Agreement, each outstanding Share was cancelled and automatically converted into the right to receive $31.35 in cash, without interest, and minus any applicable withholding taxes. For purposes of Rule 16b-3 of the Exchange Act, Patterson's Board of Directors approved the disposition of all equity securities by the Reporting Person in connection with the merger. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	94,477	$0.00	$0.00	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · nonDerivative · entry 3 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 398,185 F1 · kind: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement). F4 · kind: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2024 and held by the Reporting Person immediately prior to the closing of the Merger. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	60,132	$0.00	$0.00	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,708 F1 · kind: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement). F3 · kind: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2023 and held by the Reporting Person immediately prior to the closing of the Merger. Read SEC document
April 17, 2025 Filed Apr 17, 2025 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	20,840	$0.00	$0.00	Disclosure SEC source: 0000950170-25-055158 · ownership.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,576 F1 · kind: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement). F2 · kind: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2022 and held by the Reporting Person immediately prior to the closing of the Merger. Read SEC document
December 09, 2024 Filed Dec 9, 2024 18:00 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	SaleCommon Stock	1,962	$23.08	$45,277.86	Disclosure SEC source: 0000950170-24-134653 · ownership.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,736 F3 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 Plan adopted by Reporting Person on September 25, 2023 Amended March 12, 2024. F2 · balance_after: Includes an aggregate 131,233 RSUs awarded in the years 2022 through 2024 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon employment as follows: 44,948 units vest on 7/1/2025, 13,226 units vest on 12/5/2025, 41,504 units vest on 7/1/2026 and 31,555 units vest on 7/1/2027. Read SEC document
December 05, 2024 Filed Dec 9, 2024 18:00 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	5,374	$22.83	$122,688.42	Disclosure SEC source: 0000950170-24-134653 · ownership.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 224,698 F1 · kind: Represents shares of common stock withheld to satisfy a portion of tax liability upon the lapse of restrictions on restricted stock units ("RSUs") issued pursuant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). F2 · balance_after: Includes an aggregate 131,233 RSUs awarded in the years 2022 through 2024 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon employment as follows: 44,948 units vest on 7/1/2025, 13,226 units vest on 12/5/2025, 41,504 units vest on 7/1/2026 and 31,555 units vest on 7/1/2027. Read SEC document
September 17, 2024 Filed Sep 19, 2024 01:12 UTC	Silk Road Medical Inc SILK · Entity 87417	Disposition to issuerStock Option (right to buy) · Derivative	8,910	$7.50 Strike: $20.00	$66,825.00	Disclosure SEC source: 0001140361-24-041431 · form4.xml · derivative · entry 4 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,910 shares Expires 2029-04-03 F6 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. Read SEC document
September 17, 2024 Filed Sep 19, 2024 01:12 UTC	Silk Road Medical Inc SILK · Entity 87417	Disposition to issuerStock Option (right to buy) · Derivative	29,206	$15.35 Strike: $12.15	$448,312.10	Disclosure SEC source: 0001140361-24-041431 · form4.xml · derivative · entry 3 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,206 shares Expires 2028-03-22 F5 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $448,312.10, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. Read SEC document
September 17, 2024 Filed Sep 19, 2024 01:12 UTC	Silk Road Medical Inc SILK · Entity 87417	Disposition to issuerStock Option (right to buy) · Derivative	146,031	$21.39 Strike: $6.11	$3,123,603.09	Disclosure SEC source: 0001140361-24-041431 · form4.xml · derivative · entry 2 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 146,031 shares Expires 2028-03-22 F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $3,123,603.09, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. Read SEC document
September 17, 2024 Filed Sep 19, 2024 01:12 UTC	Silk Road Medical Inc SILK · Entity 87417	Disposition to issuerCommon Stock	12,610	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-041431 · form4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2 · price: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F3 · price: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions. Read SEC document
July 16, 2024 Filed Jul 16, 2024 16:38 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	SaleCommon Stock	7,216	$24.99	$180,327.84	Disclosure SEC source: 0000950170-24-083949 · ownership.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,072 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 Plan adopted by Reporting Person on September 25, 2023 Amended March 12, 2024. F2 · balance_after: Includes an aggregated of 144,455 restricted stock units ("RSUs") awarded in the years 2022 through 2024 to Reporting Person pursuant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). The RSUs vest contingent upon continued employment as follows: 13,221 units vest on 12/5/2024, 44,948 units vest on 7/1/2025, 13,227 units vest on 12/5/2025, 41,504 units vest on 7/1/2026, 31,555 units vest on 7/1/2027. Read SEC document
July 03, 2024 Filed Jul 8, 2024 10:53 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	SaleCommon Stock	5,875	$23.71	$139,322.10	Disclosure SEC source: 0000950170-24-081971 · ownership.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,288 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 Plan adopted by Reporting Person on September 25, 2023 Amended March 12, 2024. F2 · balance_after: Includes an aggregated of 144,455 restricted stock units ("RSUs") awarded in the years 2022 through 2024 to Reporting Person pursuant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). The RSUs vest contingent upon continued employment as follows: 13,221 units vest on 12/5/2024, 44,948 units vest on 7/1/2025, 13,227 units vest on 12/5/2025, 41,504 units vest on 7/1/2026, 31,555 units vest on 7/1/2027. Read SEC document
July 01, 2024 Filed Jul 3, 2024 10:42 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	94,477	$24.08	$2,275,006.16	Disclosure SEC source: 0000950170-24-081138 · ownership.xml · nonDerivative · entry 4 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,163 F5 · kind: Represents RSUs awarded on 7/1/2024 to Reporting Person pursuant to the Plan. The RSUs awarded vest, assuming continued employment, 33.3% on 7/1/2025, 33.3% on 7/1/2026 and 33.4% on 7/1/2027. F2 · balance_after: Includes an aggregate of 49,978 RSUs awarded in the years 2022 through 2023 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 13,221 units vest on 12/5/2024, 13,487 units vest on 7/1/2025, 13,227 units vest on 12/5/2025 and 10,043 units vest on 7/1/2026. Read SEC document
July 01, 2024 Filed Jul 3, 2024 10:42 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	4,888	$24.08	$117,703.04	Disclosure SEC source: 0000950170-24-081138 · ownership.xml · nonDerivative · entry 3 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,686 F4 · kind: Represents shares of common stock withheld to satisfy a portion of tax liability upon the vesting of performance share units. F2 · balance_after: Includes an aggregate of 49,978 RSUs awarded in the years 2022 through 2023 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 13,221 units vest on 12/5/2024, 13,487 units vest on 7/1/2025, 13,227 units vest on 12/5/2025 and 10,043 units vest on 7/1/2026. Read SEC document
July 01, 2024 Filed Jul 3, 2024 10:42 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	15,973	$24.08	$384,629.84	Disclosure SEC source: 0000950170-24-081138 · ownership.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,574 F3 · kind: Represents shares earned upon satisfaction of performance criteria applicable to non-derivative performance share units. F2 · balance_after: Includes an aggregate of 49,978 RSUs awarded in the years 2022 through 2023 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 13,221 units vest on 12/5/2024, 13,487 units vest on 7/1/2025, 13,227 units vest on 12/5/2025 and 10,043 units vest on 7/1/2026. Read SEC document
July 01, 2024 Filed Jul 3, 2024 10:42 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	4,322	$24.08	$104,073.76	Disclosure SEC source: 0000950170-24-081138 · ownership.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,601 F1 · kind: Represents shares of common stock withheld to satisfy a portion of tax liability upon the lapse of restrictions on restricted stock units ("RSUs") issued pursuant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). F2 · balance_after: Includes an aggregate of 49,978 RSUs awarded in the years 2022 through 2023 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 13,221 units vest on 12/5/2024, 13,487 units vest on 7/1/2025, 13,227 units vest on 12/5/2025 and 10,043 units vest on 7/1/2026. Read SEC document
June 18, 2024 Filed Jun 21, 2024 22:49 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantCommon Stock	5,859	$0.00	$0.00	Disclosure SEC source: 0001593968-24-000887 · primary_01.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,610 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 06, 2024 Filed Jun 10, 2024 23:31 UTC	Sight Sciences, Inc. SGHT · Entity 5537	GrantCommon Stock	17,366	$0.00	$0.00	Disclosure SEC source: 0000950170-24-071518 · ownership.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,460 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $120,000 divided by the closing price of the Common Stock on the grant date, June 6, 2024. The RSUs vest on the earlier of June 6, 2025 and the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) 15,094 shares of Common Stock, (ii) 17,366 RSUs, which are subject to vesting as reported herein, and (iii) 85,000 shares of Common Stock, which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 6, 2024. Read SEC document
December 06, 2023 Filed Dec 7, 2023 17:18 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	SaleCommon Stock	1,868	$26.58	$49,651.44	Disclosure SEC source: 0001209191-23-057743 · doc4.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,923 F3 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on April 5, 2023. F2 · balance_after: Includes an aggregate of 66,713 restricted stock units ("RSUs") awarded in the years 2021 through 2023 to Reporting Person pursuant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). The RSUs vest contingent upon continued employment as follows: 16,735 units vest 7/1/2024, 13,221 units vest 12/5/2024, 13,488 units vest 7/1/2025, 13,227 units vest on 12/5/2025 and 10,042 units vest 7/1/2026. Read SEC document
December 05, 2023 Filed Dec 7, 2023 17:18 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	5,748	$26.59	$152,839.32	Disclosure SEC source: 0001209191-23-057743 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,791 F1 · kind: Represents shares of common stock withheld for payment of taxes incurred upon the lapse of restrictions on restricted stock units ("RSUs") issued pursuant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). F2 · balance_after: Includes an aggregate of 66,713 restricted stock units ("RSUs") awarded in the years 2021 through 2023 to Reporting Person pursuant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). The RSUs vest contingent upon continued employment as follows: 16,735 units vest 7/1/2024, 13,221 units vest 12/5/2024, 13,488 units vest 7/1/2025, 13,227 units vest on 12/5/2025 and 10,042 units vest 7/1/2026. Read SEC document
July 18, 2023 Filed Jul 19, 2023 17:01 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	SaleCommon Stock	5,620	$32.48	$182,553.34	Disclosure SEC source: 0001209191-23-042756 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,539 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on April 5, 2023. F2 · balance_after: Includes an aggregate of 79,934 restricted stock units ("RSUs") awarded in the years 2020 through 2023 to Reporting Person pursuant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). The RSUs vest contingent upon continued employment as follows: 13,210 units vest 12/1/2023, 16,735 units vest 7/1/2024, 13,210 units vest 12/1/2024, 13,488 units vest 7/1/2025, 13,249 units vest on 12/1/2025 and 10,042 units vest 7/1/2026. Read SEC document
July 14, 2023 Filed Jul 18, 2023 17:03 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	13,037	$32.07	$418,096.59	Disclosure SEC source: 0001209191-23-042607 · doc4.xml · nonDerivative · entry 3 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,159 F4 · kind: Represents shares of common stock withheld to satisfy a portion of tax liability upon the vesting of performance share units. F2 · balance_after: Includes an aggregate of 79,934 RSUs awarded in the years 2020 through 2023 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 13,210 units vest 12/1/2023, 16,735 units vest 7/1/2024, 13,210 units vest 12/1/2024, 13,488 units vest 7/1/2025, 13,249 units vest on 12/1/2025 and 10,042 units vest 7/1/2026. Read SEC document
July 14, 2023 Filed Jul 18, 2023 17:03 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	28,867	$32.07	$925,764.69	Disclosure SEC source: 0001209191-23-042607 · doc4.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,196 F3 · kind: Represents shares earned upon satisfaction of performance criteria applicable to non-derivative performance share units. F2 · balance_after: Includes an aggregate of 79,934 RSUs awarded in the years 2020 through 2023 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 13,210 units vest 12/1/2023, 16,735 units vest 7/1/2024, 13,210 units vest 12/1/2024, 13,488 units vest 7/1/2025, 13,249 units vest on 12/1/2025 and 10,042 units vest 7/1/2026. Read SEC document
July 14, 2023 Filed Jul 18, 2023 17:03 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	4,490	$32.07	$143,994.30	Disclosure SEC source: 0001209191-23-042607 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,329 F1 · kind: Represents shares of common stock withheld for payment of taxes incurred upon the lapse of restrictions on restricted stock units ("RSUs") issued purusant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). F2 · balance_after: Includes an aggregate of 79,934 RSUs awarded in the years 2020 through 2023 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 13,210 units vest 12/1/2023, 16,735 units vest 7/1/2024, 13,210 units vest 12/1/2024, 13,488 units vest 7/1/2025, 13,249 units vest on 12/1/2025 and 10,042 units vest 7/1/2026. Read SEC document
July 05, 2023 Filed Jul 6, 2023 14:56 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	SaleCommon Stock	1,666	$32.34	$53,878.44	Disclosure SEC source: 0001209191-23-041478 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,819 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on April 5, 2023. F2 · balance_after: Includes an aggregate of 91,071 restricted stock units ("RSUs") awarded in the years 2020 through 2023 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 11,137 units vest 7/14/2023, 13,210 units vest 12/1/2023, 16,735 units vest 7/1/2024, 13,210 units vest 12/1/2024, 13,488 units vest 7/1/2025, 13,249 units vest on 12/1/2025 and 10,042 units vest 7/1/2026. Read SEC document
July 01, 2023 Filed Jul 5, 2023 19:39 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantEmployee Stock Options · Derivative	93,633	$33.26 Strike: $33.26	$3,114,233.58	Disclosure SEC source: 0001209191-23-041340 · doc4.xml · derivative · entry 4 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,633 Underlying: Common Stock · 93,633 shares Expires 2033-07-01 F5 · kind: Stock options granted pursuant to the Plan on 7/1/2023. F6 · derivative.exercise_date: Options are exercisable as follows: 33.3% on 7/1/2024, 33.3% on 7/1/2025 and 33.4% on 7/1/2026. Read SEC document
July 01, 2023 Filed Jul 5, 2023 19:39 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	30,066	$33.26	$999,995.16	Disclosure SEC source: 0001209191-23-041340 · doc4.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,485 F3 · kind: Represents RSUs awarded on 7/1/2023 to Reporting Person pursuant to the Plan. The RSUs awarded vest, assuming continued employment, 33.3% on 7/1/2024, 33.3% on 7/1/2025 and 33.4% on 7/1/2026. F2 · balance_after: Includes an aggregate of 61,005 RSUs awarded in the years 2020 through 2022 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 11,137 units vest 7/14/2023, 13,210 units vest 12/1/2023, 6,723 units vest 7/1/2024, 13,210 units vest 12/1/2024, 3,476 units vest 7/1/2025 and 13,249 units vest on 12/1/2025. Read SEC document
July 01, 2023 Filed Jul 5, 2023 19:39 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	2,282	$33.26	$75,899.32	Disclosure SEC source: 0001209191-23-041340 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,419 F1 · kind: Represents shares of common stock withheld for payment of taxes incurred upon the lapse of restrictions on restricted stock units ("RSUs") issued purusant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). F2 · balance_after: Includes an aggregate of 61,005 RSUs awarded in the years 2020 through 2022 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 11,137 units vest 7/14/2023, 13,210 units vest 12/1/2023, 6,723 units vest 7/1/2024, 13,210 units vest 12/1/2024, 3,476 units vest 7/1/2025 and 13,249 units vest on 12/1/2025. Read SEC document
June 21, 2023 Filed Jun 23, 2023 21:39 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantCommon Stock	4,691	$0.00	$0.00	Disclosure SEC source: 0001593968-23-001037 · primary_01.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,751 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 08, 2023 Filed Jun 12, 2023 21:47 UTC	Sight Sciences, Inc. SGHT · Entity 5537	GrantCommon Stock	15,094	$0.00	$0.00	Disclosure SEC source: 0000899243-23-015388 · doc4.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,440 F3 · shares: Reflects a grant of RSUs made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of Common Stock. The number of RSUs granted is equal to approximately $120,000 of shares of Common Stock as determined by the closing price on the grant date, June 8, 2023. The RSUs vest on the earlier of June 8, 2024 and the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) the 11,940 shares of Common Stock issued upon the vesting of the RSUs reported on this Form 4 and (ii) 62,500 shares of common stock the Reporting Person has the right to acquire upon the vesting of stock options within 60 days of June 8, 2023. Read SEC document
June 08, 2023 Filed Jun 12, 2023 21:47 UTC	Sight Sciences, Inc. SGHT · Entity 5537	GrantCommon Stock	11,940	$0.00	$0.00	Disclosure SEC source: 0000899243-23-015388 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,440 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person on June 8, 2022 under the Issuer's Non-Employee Director Compensation Program, as reported in Table II on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on August 5, 2022. Each RSU represented a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The RSUs vested on June 8, 2023. F2 · balance_after: Includes (i) the 11,940 shares of Common Stock issued upon the vesting of the RSUs reported on this Form 4 and (ii) 62,500 shares of common stock the Reporting Person has the right to acquire upon the vesting of stock options within 60 days of June 8, 2023. Read SEC document
December 05, 2022 Filed Dec 6, 2022 17:44 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantEmployee Stock Options · Derivative	134,033	$28.99 Strike: $28.99	$3,885,616.67	Disclosure SEC source: 0001209191-22-060086 · doc4.xml · derivative · entry 3 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,033 Underlying: Common Stock · 134,033 shares Expires 2032-12-05 F4 · kind: Stock options granted pursuant to the Plan on 12/5/2022. F5 · derivative.exercise_date: Options are excercisable as follows: 33.3% on 12/5/2023, 33.3% on 12/5/2024 and 33.4% on 12/5/2025. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.